PTC Therapeutics Inc (PTCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
PTC Therapeutics Inc (PTCT) Financials: Revenue, Profit and Cash Flow
PTC Therapeutics reported revenue of $1.73B for the fiscal year ended Dec 31, 2025, up 114.5% from the year before. That year, net income was $682.64M with a net margin of 39.4%, operating cash flow was $711.20M and free cash flow was $702.34M. The quarter ended Jun 30, 2026 had revenue of $360.52M and net income of $83.50M.
Revenue and Margins
The operating margin was 50.1% in the fiscal year ended Dec 2025, the highest of the 8 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $82.70M, a compound annual rate of 40.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.73B | +114.5% | 100.0% | 50.1% | 39.4% |
| Dec 2024 | $806.78M | -14.0% | 92.9% | -37.5% | -45.0% |
| Dec 2023 | $937.82M | +34.2% | 100.0% | -46.9% | -66.8% |
| Dec 2022 | $698.80M | +29.7% | 93.6% | -64.0% | -80.0% |
| Dec 2021 | $538.59M | +41.4% | 94.0% | -69.5% | -97.3% |
| Dec 2020 | $380.77M | +24.0% | 95.0% | -113.4% | -115.1% |
| Dec 2019 | $306.98M | +16.0% | 96.0% | -78.6% | -82.0% |
| Dec 2018 | $264.73M | +36.2% | 95.2% | -43.7% | -48.4% |
| Dec 2017 | $194.39M | +135.0% | 97.6% | -33.1% | -40.6% |
| Dec 2016 | $82.70M | N/A | 100.0% | -159.7% | -171.8% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $806.78M | $937.82M | $698.80M | $538.59M | $380.77M | $306.98M | $264.73M | $194.39M | $82.70M |
| Cost of revenue | $0 | $57.40M | $0 | $44.68M | $32.33M | $18.94M | $12.13M | $12.67M | $4.58M | $0 |
| Gross profit | $1.73B | $749.38M | $937.82M | $654.12M | $506.26M | $361.82M | $294.85M | $252.06M | $189.81M | $82.70M |
| Research and development | $455.25M | $534.48M | $666.56M | $651.50M | $540.68M | $477.64M | $257.45M | $171.98M | $117.46M | $117.63M |
| Operating income | $866.93M | -$302.57M | -$439.50M | -$447.41M | -$374.44M | -$431.77M | -$241.16M | -$115.69M | -$64.29M | -$132.06M |
| Net income | $682.64M | -$363.30M | -$626.60M | -$559.02M | -$523.90M | -$438.16M | -$251.58M | -$128.08M | -$79.00M | -$142.11M |
| EBITDA | $870.86M | -$231.69M | -$193.11M | -$364.17M | -$361.04M | -$260.28M | -$196.48M | -$89.38M | -$46.92M | -$127.79M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $360.52M | $272.55M | $164.68M | $211.01M | $178.88M | $1.18B | $213.17M | $196.79M | $186.70M | $210.12M | $307.06M | $196.58M |
| Gross profit | $340.60M | $244.52M | $188.96M | $211.01M | $167.46M | $1.18B | $186.04M | $196.79M | $171.18M | $195.38M | $343.42M | $187.08M |
| Operating income | $148.98M | $44.96M | -$71.35M | $3.02M | -$34.96M | $970.23M | -$162.39M | -$54.51M | -$40.22M | -$45.45M | $5.82M | -$118.16M |
| Net income | $83.50M | -$2.81M | -$134.97M | $15.90M | -$64.85M | $866.56M | -$65.89M | -$106.65M | -$99.18M | -$91.58M | -$155.79M | -$132.97M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $286.63M by $698.02M. Shareholder equity was negative, at -$205.31M, as total liabilities of $3.10B exceeded total assets of $2.90B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $391.65M | $269.35M |
| Current assets | $2.27B | $1.37B | $1.22B | $693.78M | $954.37M | $1.23B | $779.28M | $320.86M | $249.06M | $261.29M |
| Cash and equivalents | $984.65M | $779.71M | $594.00M | $279.83M | $189.72M | $208.81M | $288.03M | $227.59M | $111.79M | $58.32M |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768.50M | $235.22M | $149.76M |
| Short-term debt | $286.63M | $0 | $210.32M | $84.52M | $149.54M | $0 | $20.00M | $11.67M | $0 | $40.87M |
| Long-term debt | $0 | $285.41M | $284.21M | $571.72M | $281.89M | $309.14M | $293.86M | $141.35M | $144.97M | $98.22M |
| Shareholder equity | -$205.31M | -$1.10B | -$818.55M | -$347.09M | $1.44M | $481.98M | $594.33M | $350.73M | $156.44M | $119.58M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.25B | $2.87B | $2.91B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | $1.90B | $1.26B |
| Total liabilities | $3.42B | $3.05B | $3.12B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | $2.71B | $1.93B |
| Cash and equivalents | $1.05B | $833.99M | $984.65M | $672.62M | $1.02B | $1.48B | $779.71M | $526.00M | $654.78M | $548.36M | $594.00M | $165.16M |
| Shareholder equity | -$165.36M | -$180.47M | -$205.31M | -$155.76M | -$206.55M | -$185.76M | -$1.10B | -$1.05B | -$980.18M | -$893.92M | -$818.55M | -$670.81M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.8% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $711.20M | -$107.69M | -$158.42M | -$356.65M | -$251.33M | -$194.07M | -$98.64M | -$27.64M | -$10.06M | -$103.57M |
| Capital expenditures | $8.86M | $6.50M | $28.44M | $32.02M | $28.21M | $17.84M | $13.76M | $7.10M | $3.10M | $1.78M |
| Free cash flow | $702.34M | -$114.19M | -$186.86M | -$388.67M | -$279.55M | -$211.91M | -$112.40M | -$34.74M | -$13.16M | -$105.34M |
| Investing cash flow | -$861.98M | $44.18M | -$176.74M | $290.18M | $219.18M | -$561.55M | -$387.24M | -$42.61M | $13.12M | $104.48M |
| Financing cash flow | $331.09M | $255.87M | $646.40M | $167.95M | $20.88M | $668.72M | $613.21M | $131.57M | $44.22M | $968.00K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $129.11M | -$59.04M | -$34.27M | -$66.30M | -$58.33M | $870.10M | -$30.00M | -$76.99M | -$71.45M | $70.76M | -$100.29M | -$14.52M |
| Capital expenditures | $2.19M | $1.20M | $2.37M | $3.44M | $1.25M | $1.72M | $3.77M | $522.00K | $7.38M | $9.59M | $5.57M | $6.36M |
| Free cash flow | $126.92M | -$60.24M | -$36.65M | -$69.75M | -$59.58M | $868.38M | -$33.77M | -$77.51M | -$78.83M | $61.17M | -$105.85M | -$20.88M |
Frequently Asked Questions About PTCT
What is PTC Therapeutics' annual revenue?
PTC Therapeutics reported revenue of $1.73B for the fiscal year ended Dec 31, 2025.
How fast is PTC Therapeutics' revenue growing?
Revenue was up 114.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 35.3%.
Is PTC Therapeutics profitable?
Yes. PTC Therapeutics reported net income of $682.64M for the fiscal year ended Dec 31, 2025, with a net margin of 39.4%.
How much free cash flow does PTCT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $711.20M minus capital expenditures of $8.86M produced free cash flow of $702.34M.
How much debt does PTC Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $286.63M and cash and equivalents of $984.65M.
PTCT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors